Based on these functions, we summarise several urological tumour‐specific strategies targeting this pathway, including metabolic interventions (Trp deprivation/IDO1 inhibitors),107 delivery systems (RC@RMPs,93 LNPs40), palmitoylation inhibitors (2‐BP)10 and DNA damage repair inhibitors (PARPi).101. This evidence concerns the gene IDO1 and neoplasm.